Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Sunshine Biopharma (SBFM) over the last 12 years, with Dec 2024 value amounting to $30.6 million.

  • Sunshine Biopharma's Liabilities and Shareholders Equity rose 4.76% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 3.88%. This contributed to the annual value of $30.6 million for FY2024, which is 11.75% up from last year.
  • Sunshine Biopharma's Liabilities and Shareholders Equity amounted to $30.6 million in FY2024, which was up 11.75% from $27.3 million recorded in FY2023.
  • Over the past 5 years, Sunshine Biopharma's Liabilities and Shareholders Equity peaked at $30.6 million during FY2024, and registered a low of $1.0 million during FY2020.
  • Over the past 3 years, Sunshine Biopharma's median Liabilities and Shareholders Equity value was $29.2 million (recorded in 2022), while the average stood at $29.1 million.
  • Per our database at Business Quant, Sunshine Biopharma's Liabilities and Shareholders Equity skyrocketed by 1,227.52% in 2022 and then declined by 6.49% in 2023.
  • Sunshine Biopharma's Liabilities and Shareholders Equity (Yearly) stood at $1.0 million in 2020, then spiked by 110.71% to $2.2 million in 2021, then spiked by 1,227.52% to $29.2 million in 2022, then fell by 6.49% to $27.3 million in 2023, then rose by 11.75% to $30.6 million in 2024.